<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Multiple synchronous verrucous carcinomas of the scalp in the background of generalized verruca vulgaris.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Multiple synchronous verrucous carcinomas of the scalp in the background of generalized verruca vulgaris." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe7/4372913/a718528fa3e6/IJD-60-182-g003.jpg"/> </div> <div class="text-side"> <h1>Multiple synchronous verrucous carcinomas of the scalp in the background of generalized verruca vulgaris.</h1> <p>(a and b) Tumor composed of marked verrucous hyperplasia of squamous epithelium with reduplication, down growths, pushing borders, and mild nuclear atypia; the clinicopathological picture was suggestive of a verrucous carcinoma (hematoxylin and eosin (H and E), ×20). (c) Verrucous carcinoma showing mild focal immunopositivity for p16 (H and E, ×10). (d) Figure showing the polymerase chain reaction (PCR) amplification of the sample deoxyribonucleic acid (DNA) showing human papillomavirus (HPV) infection using consensus primer GP5+ and GP6+ showing lane 1-7 in the PCR ladder; Lane 3 - positive control (HeLa cells), lane 4 - tumor sample; and lane 6 - negative control</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25814709/" target="_blank">25814709</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>